- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track Dermata continues discussions with potential botulinum toxin partners for DMT410 Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis -SAN DIEGO, CA / ACCESSWIRE / May 15, 202.
Dermata Therapeutics Provides Corporate Update and Reports First Quarter ... pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Dermata Therapeutics : Provides Corporate Update and Reports First Quarter 2024 Financial Results - Form 8-K marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Dermata to Begin Enrolling Patients in DMT310 Phase 3 Acne Clinical Program in December 2023 based on Agreement with FDA on the Phase 3 Protocols bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.